Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approaches
Abstract
Cancer drug discoverers and developers are blessed and cursed with a plethora of drug targets in the tumor cells themselves and the surrounding stromal elements. This bounty of targets has, at least in part, inspired the rapid increase in the number of clinically available small-molecule, biological, and cellular therapies for solid and hematological malignancies. Among the most challenging questions in cancer therapeutics, especially for small molecules, is how to approach loss-of-function gene mutations or deletions that encode tumor suppressors. A second mounting question is what are the optimal drug combinations. This article will briefly review the recent advances in exploitingin vitroandin vivosynthetic lethal screens to expose cancer pharmacological targets with the goal of developing new drug combinations.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 12, 2018
- Source ID
- 10.12688/f1000research.13679.1
Entities
People
- John S. Lazo
Organizations
- Cure Alzheimer's Fund
- National Institutes of Health
- United States Department of Defense